What question did this study set out to answer?

To investigate how CP-25 affects dendritic cell differentiation and its implications for diabetic kidney disease.

April 15, 2026

Paeoniflorin‐6′‐O‐Benzenesulfonate Mediates Dendritic Cell Differentiation to Alleviate Diabetic Kidney Disease

Key Points

To investigate how CP-25 affects dendritic cell differentiation and its implications for diabetic kidney disease.
Examined the effects of CP-25 on dendritic cell differentiation.
Analyzed inflammation modulation through signaling pathways.
Focused on GRK2-mediated JAK2-STAT3-SOCS3 signaling pathways.
CP-25 successfully modulated dendritic cell function.
Inhibition of inflammation was observed via the targeted signaling pathway.
Alleviation of diabetic kidney disease symptoms was achieved.

Abstract

CP-25 exhibits therapeutic efficacy against kidney injury in DKD. Its primary mechanism involves modulating the differentiation and function of DCs, which affects the activation of T cells. In terms of mechanism, CP-25 targets the GRK2-mediated JAK2-STAT3-SOCS3 signalling pathway to inhibit inflammation for alleviating DKD.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Wei Liang

Dongchun Zhu

Lei Xiao

Journals

Clinical and Experimental Pharmacology and Physiology

Actions

Institutions

Chinese University of Hong Kong

Anhui Medical University

Huadong Hospital

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Paeoniflorin‐6′‐O‐Benzenesulfonate Mediates Dendritic Cell Differentiation to Alleviate Diabetic Kidney Disease

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study